NCT00732368已完成3 期
A Long-term Study of Mometasone Furoate in Patients With Perennial Allergic Rhinitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 98
- 主要终点
- Change from Baseline in 4 nasal symptom score.
研究概览
简要总结
This study examined the safety and effectiveness of long-term administration of mometasone nasal spray in patients with perennial allergic rhinitis. Patients received mometasone for 12 weeks plus an additional 12 weeks if patient agreed to continue. Dose of mometasone could be decreased or increased during the study based on patient's response.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Moderate to severe perennial allergic rhinitis, >16 years of age
排除标准
- •Patients with coexisting tuberculous disease or lower respiratory tract infection and patients who have acute upper respiratory tract infection, acute pharyngolaryngitis, or acute tonsillitis judged by the investigator to require treatment
- •Patients with coexisting infections or systemic mycosis for which there are no effective treatment
- •Patients with coexisting mycosis in the nasal and paranasal cavities
- •Patients who are judged to require prohibited concomitant drugs during the clinical study
- •Patients who have experienced recent nasal septum ulcers, nasal surgery, or nasal trauma, which have not yet healed
- •Patients with a history of hypersensitivity to steroids or mometasone furoate
- •Patients who are pregnant or nursing or who may be pregnant and patients or whose partner desires to become pregnant during the study period
- •Patients with severe hepatic disorder, renal disorder, cardiac disease, diabetes mellitus, hypertension, or hematological disease or other serious coexisting diseases and whose general condition is poor as judged by the investigators.
- •Patients allergic to pollen and the pollen release season occurs in the 7 days before the start of treatment
- •Patients diagnosed with vasomotor rhinitis or eosinophilic rhinitis
- •Patients with nasal conditions which may interfere with efficacy evaluation of the study drug
- •Patients who develop a disease which may affect nasal symptoms in the 7 days before the start of treatment
- •Patients who are participating or have participated in a clinical trial of an investigational drug within 120 days before the day of obtaining informed consent
- •Patients for whom the period of discontinuation of previous treatment before the start of study drug administration indicated Table 2 is not adequate or who cannot avoid the use of these drugs
- •Patients undergoing specific desensitization therapy or nonspecific allassotherapy (Histaglobin, vaccine therapy, etc.) or who had discontinued such therapy within 90 days prior to obtaining informed consent. (However, patients need not be excluded if therapy has been ongoing for at least 180 days before obtaining informed consent and maintenance therapy is now being conducted.)
研究组 & 干预措施
Mometasone Nasal Spray
Experimental
Open-label. Two sprays per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
干预措施: Mometasone furoate (Drug)
结局指标
主要结局
Change from Baseline in 4 nasal symptom score.
时间窗: All visits starting 2 weeks prior to treatment until 5 to 9 days after last administration of treatment
次要结局
- Individual nasal symptom scores (sneezing, attack, rhinorrhea, nasal congestion, and nasal itching)(All visits starting 2 weeks prior to treatment until 5 to 9 days after last administration of treatment)
- Overall improvement (combination of nasal symptoms and rhinoscopic nasal findings)(All visits during which patient is receiving drug (includes the 12 week drug administration period plus the 12 week additional drug administration period))
- Adverse events(Throughout the study once initial treatment has started and until 5 to 9 days after last administration of treatment.)
- Laboratory tests(At baseline, and 4, 12, and 24 weeks after treatment)
研究者
相似试验
已完成
3 期
A Study of Long-term Administration of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06333AM1)Rhinitis, Allergic, PerennialNCT01165424Organon and Co80
已完成
3 期
Safety and Efficacy of Mometasone Furoate Nasal Spray With the Addition of Loratadine Versus Placebo in Participants With Seasonal Allergic Rhinitis (C94-145)Rhinitis, AllergicNCT03855228Organon and Co704
已完成
3 期
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)Perennial Allergic RhinitisNCT00783224Organon and Co351
进行中（未招募）
1 期
An exploratory study of mometasone furoate nasal spray in patients with moderate-severe persistent allergic rhinitis and intermittent asthma: effects on the quality of life evaluated with the Rhinasthma questionnaire - NDpersistent allergic rhinitis and concomitant intermittent asthmaMedDRA version: 9.1 Level: LLT Classification code 10039085 Term: Rhinitis allergicEUCTR2007-004683-45-ITSCHERING-PLOUGH56
已完成
3 期
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)Seasonal Allergic RhinitisNCT00453063Organon and Co426